{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060865","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.692952+00:00","generated_at":"2026-06-02T00:22:05.572705+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cellectar Q1 net loss $0.74/share; cash $40M; WM study data in June","bullets":["Net loss of $21.6M ($0.74/share) in Q1 2024 vs $8.6M ($0.76/share) in Q1 2023; cash $40.0M.","CLOVER WaM pivotal study met primary endpoint: major response rate 61%; full data in June; NDA submission on track for H2 2024.","Cash $40.0M as of March 31, 2024, expected to fund operations into Q4 2024; net cash used in operations ~$13M in Q1.","Phase 1b pediatric high-grade glioma study enrolled first patient; data expected H2 2024.","Preclinical data for alpha-emitting CLR 121225 in pancreatic cancer; phase 1 planned by Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060865","json":"https://secwatch.observer/filing/0001104659-24-060865.json","markdown":"https://secwatch.observer/filing/0001104659-24-060865.md","text":"https://secwatch.observer/filing/0001104659-24-060865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924060865/0001104659-24-060865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924060865/tm2414381d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:22:05.572705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7d2e0118c36e24293b586cda31959713fc84eec","claim":"Cellectar Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income The net loss attributable to common stockholders for the three months ended March 31, 2024, was ($21.6) million, or $(0., EPS $(0.74) per share.","evidence_excerpt":"Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924060865/0001104659-24-060865-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"The net loss attributable to common stockholders for the three months ended March 31, 2024, was ($21.6) million, or $(0."},{"label":"EPS","value":"$(0.74) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}